Apostolos Papachristos
YOU?
Author Swipe
View article: Predictors of Bilateral Disease in Low-Risk Papillary Thyroid Cancer: Histopathologic Insights and Preoperative Ultrasonography
Predictors of Bilateral Disease in Low-Risk Papillary Thyroid Cancer: Histopathologic Insights and Preoperative Ultrasonography Open
Background With the current shift toward de-escalation of surgical management in low-risk papillary thyroid cancer (PTC), understanding predictors and the clinical significance of additional tumors in the contralateral lobe is important. T…
View article: Editorial: Utilization of pharmacogenomics in clinical practice
Editorial: Utilization of pharmacogenomics in clinical practice Open
View article: High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma Open
Background Cemiplimab (Libtayo ® ), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who are not candid…
View article: Model-based ‘learn and confirm approach’ demonstrates similarity of cemiplimab exposure in pediatric and adult populations
Model-based ‘learn and confirm approach’ demonstrates similarity of cemiplimab exposure in pediatric and adult populations Open
View article: P2.05-04 Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
P2.05-04 Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Open
View article: Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics Open
Drugs’ safety and effectiveness are evaluated in randomized, dose-ranging trials in most therapeutic areas. However, this is only sometimes feasible in oncology, and dose-ranging studies are mainly limited to Phase 1 clinical trials. Moreo…
View article: Machine learning‐guided covariate selection for time‐to‐event models developed from a small sample of real‐world patients receiving bevacizumab treatment
Machine learning‐guided covariate selection for time‐to‐event models developed from a small sample of real‐world patients receiving bevacizumab treatment Open
Therapeutic outcomes in patients with metastatic colorectal cancer (mCRC) receiving bevacizumab treatment are highly variable, and a reliable predictive factor is not available. Progression‐free survival (PFS) and overall survival (OS) wer…
View article: Lurbinectedin-induced thrombocytopenia: the role of body surface area
Lurbinectedin-induced thrombocytopenia: the role of body surface area Open
View article: In Reply
In Reply Open
This letter to the editor responds to Le Louedec et al. regarding the recently published article on the correlation between bevacizumab exposure and survival in patients with metastatic colorectal cancer.
View article: Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review
Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review Open
Bevacizumab is a monoclonal antibody that targets VEGF-A and inhibits tumor angiogenesis. Bevacizumab is approved for the treatment of various cancer, including metastatic colorectal cancer (mCRC), ovarian cancer, lung cancer, and others. …
View article: Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer
Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer Open
Vascular endothelial growth factor A (VEGF-A) and intercellular adhesion molecule 1 (ICAM-1) are significant regulators of angiogenesis, an important biological process involved in carcinogenesis. Bevacizumab, an anti-VEGF monoclonal antib…
View article: The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness
The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness Open
Bladder cancer is a highly prevalent disease worldwide and is associated with a high mortality rate. Across all stages of bladder cancer, immunotherapy has now become the cornerstone of treatment. The commensal microbiome has become a majo…
View article: Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer
Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer Open
Background Bevacizumab treatment is subject to large interpatient variability in efficacy, which may partly be explained by differences in complex bevacizumab pharmacokinetic characteristics that influence bevacizumab exposure. Exposure–re…
View article: VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer Open
Bevacizumab is used to treat metastatic colorectal cancer (mCRC). However, there are still no available predictors of clinical outcomes. We investigated selected single nucleotide polymorphisms (SNPs) in the genes involved in VEGF-dependen…
View article: Do we need to adopt antifungal stewardship programmes?
Do we need to adopt antifungal stewardship programmes? Open
The presence of a multidisciplinary team, including an infection control specialist and a clinical pharmacist, would limit the prescription of advanced antifungal agents as empirical therapy. Moreover, this team would control the de-escala…
View article: 4CPS-077 Do we need to adopt antifungal stewardship programmes?
4CPS-077 Do we need to adopt antifungal stewardship programmes? Open
Background Although antimicrobial stewardship programmes are one of the highest priorities in healthcare systems, the appropriate use of antifungal agents has not been widely studied. Breakthrough infections from resistant Candida species …
View article: 4CPS-017 Misuse of novel oral anticoagulants in hospital settings
4CPS-017 Misuse of novel oral anticoagulants in hospital settings Open
Background In the past few years, the development of three novel oral anticoagulants (NOACs), which directly target thrombin or factor Xa, has brought a remarkable change in the clinical practice of anticoagulation therapy. Although they c…
View article: Direct oral anticoagulant considerations in solid organ transplantation: A review
Direct oral anticoagulant considerations in solid organ transplantation: A review Open
For more than 60 years, warfarin was the only oral anticoagulation agent available for use in the United States. In many recent clinical trials, several direct oral anticoagulants ( DOAC s) demonstrated similar efficacy with an equal or su…